|
MAGED1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.57640012155014E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.33409974576193E-10 |
| Normal-vs-Stage2 |
6.418900E-03 |
| Normal-vs-Stage3 |
6.1329999967441E-09 |
| Normal-vs-Stage4 |
3.41780004298187E-09 |
| Stage1-vs-Stage2 |
1.081180E-01 |
| Stage1-vs-Stage3 |
8.218800E-01 |
| Stage1-vs-Stage4 |
2.761400E-01 |
| Stage2-vs-Stage3 |
1.019350E-01 |
| Stage2-vs-Stage4 |
3.028200E-02 |
| Stage3-vs-Stage4 |
3.847000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.00179997630789E-09 |
| Normal-vs-AfricanAmerican |
2.918100E-02 |
| Normal-vs-Asian |
2.55010013106016E-10 |
| Caucasian-vs-AfricanAmerican |
6.687700E-02 |
| Caucasian-vs-Asian |
1.119820E-01 |
| AfricanAmerican-vs-Asian |
1.837620E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.3347999999499E-06 |
| Normal-vs-Female |
7.35411731511704E-12 |
| Male-vs-Female |
3.039800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.53960177939894E-11 |
| Normal-vs-Age(41-60Yrs) |
4.18760000009399E-08 |
| Normal-vs-Age(61-80Yrs) |
1.28759999995509E-06 |
| Normal-vs-Age(81-100Yrs) |
2.344200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.288600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.174600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.657600E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.224800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.036800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.374600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.825990E-02 |
| Classical-VS-Follicular |
7.455200E-01 |
| Classical-VS-Other |
1.542380E-01 |
| Classical-VS-Normal |
2.19240003929144E-09 |
| Tall-VS-Follicular |
1.348640E-01 |
| Tall-VS-Other |
4.375400E-01 |
| Tall-VS-Normal |
5.35610000795828E-10 |
| Follicular-VS-Other |
2.982400E-01 |
| Follicular-VS-Normal |
2.59099999999624E-06 |
| Other-VS-Normal |
3.360800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.68210000045721E-07 |
| Normal-vs-N1 |
1.64090963039598E-13 |
| N0-vs-N1 |
1.165000E-04 |
|
|
